Global Medications For Heart Failure Market Anticipated to Expand Rapidly From 2025 to 2029

 Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

What Is the Current Size and Annual Growth Rate of the Medications For Heart Failure Market?
The medications for heart failure market size has grown strongly in recent years. It will grow from $10.14 billion in 2024 to $10.79 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to the rising prevalence of cardiovascular diseases, increasing diagnosis and awareness, regulatory approvals and support, increasing R&D spending on cardiovascular drugs, and the adoption of telemedicine and remote monitoring tools.

The medications for heart failure market size is expected to see strong growth in the next few years. It will grow to " $14.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to growth in personalized and precision medicine, the rising global burden of lifestyle diseases, the pipeline of combination therapies and fixed-dose formulations, increasing clinical evidence and updated guidelines, and increasing urbanization. Major trends in the forecast period include the growth of SGLT2 inhibitors, digital health integration, remote monitoring tools and AI-driven analytics, increasing focus on HFpEF treatment, and ongoing research and development.

Get your free report sample today:
Heart Failure Drugs Market Report 2025, Size & Trends 2034 Sample

What Are the Primary Factors Driving the Medications For Heart Failure Market?
The rising prevalence of cardiovascular diseases is expected to propel the growth of the medications for the heart failure market going forward. Cardiovascular diseases refer to conditions that impact the heart and blood vessels, commonly resulting in severe issues such as heart attacks and strokes. The rise in cardiovascular diseases is largely driven by sedentary lifestyles that weaken heart and vessel health over time. As cardiovascular disease rates rise, the demand for effective treatments grows, prompting greater investment in heart failure medications. With the condition becoming more widespread, pharmaceutical companies are prioritizing the development and enhancement of therapies to better manage symptoms and improve patient outcomes. For instance, in September 2024, according to the Heart Failure Society of America (HFSA), a US-based organization of heart failure experts, around 6.7 million Americans aged 20 and older currently live with heart failure (HF), with the number projected to increase to 8.7 million by 2030, 10.3 million by 2040, and 11.4 million by 2050. Therefore, the rising prevalence of cardiovascular diseases is driving the growth of medications for the heart failure market.

How Is the Medications For Heart Failure Market Categorized Based on Key Segments?
The medications for heart failuremarket covered in this report is segmented –

1) By Drug Class: Angiotensin-Converting Enzyme (ACE) Inhibitors; Beta Blockers; Diuretics; Aldosterone Antagonists; Angiotensin II Receptor Blockers (ARBs); Other Drug Classes
2) By Route Of Administration: Oral; Intravenous; Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
4) By Application: Hospital; Clinic; Other Applications

Subsegments:
1) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril; Lisinopril; Ramipril; Captopril; Perindopril; Other Angiotensin-Converting Enzyme (ACE) Inhibitors
2) By Beta Blockers: Carvedilol; Metoprolol Succinate; Bisoprolol; Nebivolol; Other Beta Blockers
3) By Diuretics: Loop Diuretics; Thiazide Diuretics; Potassium-Sparing Diuretics; Other Diuretics
4) By Aldosterone Antagonists: Spironolactone; Eplerenone; Other Aldosterone Antagonists
5) By Angiotensin II Receptor Blockers (ARBs): Valsartan; Losartan; Candesartan; Irbesartan; Other Angiotensin II Receptor Blockers (ARBs)
6) By Other Drug Classes: Angiotensin Receptor-Neprilysin Inhibitors; Ivabradine; Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors; Hydralazine Or Isosorbide Dinitrate; Digoxin; Other Medications

What Are the Most Prominent Trends Impacting the Medications For Heart Failure Market?
Major companies operating in the medication for heart failure market are focused on developing advanced drugs, such as sodium-glucose cotransporter (SGLT) inhibitors, to provide more effective long-term management of heart failure symptoms and complications. An SGLT inhibitor is an advanced medication that targets glucose reabsorption mechanisms to manage heart failure, enhance efficiency, and optimize cardiovascular health. For instance, in May 2023, Lexicon Pharmaceuticals, a US-based biopharmaceutical company, introduced Inpefa (sotagliflozin), which received approval from the Food and Drug Administration (FDA). It is a once-daily oral tablet designed to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors. This approval marks a significant milestone for Lexicon, as Inpefa is the first dual SGLT1/SGLT2 inhibitor to reach the market, offering a new treatment option for heart failure patients across a broad range of conditions.

Who Are the Major Companies Operating in the Medications For Heart Failure Market?
Major companies operating in the medications for heart failure market are Merck & Co. Inc., Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Boehringer Ingelheim Pharmaceuticals Inc., Steris Pharma, CSPC Pharmaceutical, Hikma Pharmaceuticals PLC, Cadila Pharmaceuticals, Ionis Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Hainan Poly Pharm. Co. Ltd., Addii Biotech, Lunan Pharmaceutical Group, Mylan Laboratories Inc., Neuracle Lifesciences Private Limited, JM Laboratories, Lexicon Pharmaceuticals.

Get the detailed medications for heart failure market report today
Heart Failure Drugs Market Report 2025, Size & Trends 2034

Which Region Holds the Largest Share of the Medications For Heart Failure Market?
North America was the largest region in the medications for the heart failure market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the medications for heart failure market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:
The Business Research Company: Market Research Reports
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: The Business Research Company | LinkedIn